期刊文献+

艾拉莫德联合补肾强督汤及督灸在肾虚督寒型强直性脊柱炎中的应用效果 被引量:1

Effect of Iguratimod Tablet Combined with Bushen Qiangdu Decoction and Du Meridian Moxibustion in Patients with Ankylosing Spondylitis
下载PDF
导出
摘要 目的 探讨艾拉莫德联合补肾强督汤及督灸下调肾虚肾寒型强直性脊柱炎患者中的应用效果及对肿瘤坏死因子-a(TNF-a)、白细胞介素-6(IL-6)的影响。方法 选取烟台市中医医院收治的62例肾虚肾寒型强直性脊柱炎患者作为研究对象,分为对照组(30例)和观察组(32例)。对照组采用艾拉莫德治疗,观察组联合补肾强督汤及督灸治疗,比较两组临床效果及对患者TNF-a、IL-6的影响。结果 观察组治疗后4个月TNF-a、IL-6水平,均低于对照组(P <0.05);观察组治疗后疼痛改善时间、晨僵时间,均短于对照组(P <0.05);观察组腰背活动度增加量大于对照组(P <0.05);两组不良反应发生率差异无统计学意义(P> 0.05)。结论 艾拉莫德联合补肾强督汤及督灸用于肾虚肾寒型强直性脊柱炎患者中能降低炎症因子水平,安全性较高。 Objective To explore the application effect of Iguratimod Tablet combined with kidney-tonifying and regulating moxibustion in patients with kidney-deficiency cold-type ankylosing spondylitis.Methods A total of 62 cases of kidney-deficiency cold-type ankylosing spondylitis treated Yantai Hospital of Traditional Chinese Medicine from May 2016 to March 2018 were selected as study objects,divided into control group(30 cases)and observation group(32 cases).The control group was treated with Iguratimod Tablet,and the observation group was combined with kidney-tonifying and Du meridian moxibustion.The clinical effects of the two groups and the effects on patients TNF-a and IL-6 were compared between groups.Results TNF-a and IL-6 levels in the observation group were all lower than those in the control group at 4 months after treatment(P<0.05).The improvement time of pain and morning stiffness in the observation group were shorter than those in the control group(P<0.05).The increase of lumbar back activity in the observation group was greater than that in the control group(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion Iguratimod Tablet combined with kidney-tonifying and Du meridian moxibustion can reduce the level of inflammatory factors in patients with kidney-deficiency cold-type ankylosing spondylitis with high safety.
作者 李晓玲 赵恒立 汪海玥 宋志超 张妍妍 齐文蓉 杨峰 齐丽丽 卢瑶 LI Xiaoling;ZHAO Hengli;WANG Haiyue;SONG Zhichao;ZHANG Yanyan;QI Wenrong;YANG Feng;QI Lili;LU Yao(Yantai Hospital of Traditional Chinese Medicine,Yantai,Shandong 264001,China)
出处 《大医生》 2019年第3期62-63,共2页 Doctor
关键词 强直性脊柱炎 观察组 艾拉莫德 督灸 晨僵时间 腰背 补肾强督汤 炎症因子水平 iguratimod tablet bushen qiangdu decoction du meridian moxibustion
  • 相关文献

参考文献6

二级参考文献49

  • 1高晶,只德广,曾勇,张鹏,刘昌孝.艾拉莫德(T-614)的临床前药代动力学研究[J].药物评价研究,2009,32(1):19-28. 被引量:5
  • 2高洁生,谢希,吴轰,陈颖娟,李芬,田静.来氟米特和甲氨喋呤联合治疗重症类风湿关节炎短期研究[J].临床荟萃,2005,20(17):996-998. 被引量:10
  • 3王莉莎,黄烽,张江林,张莉芸,邓小虎,张亚美,李晓峰,郭军华.肿瘤坏死因子拮抗剂治疗类风湿关节炎和强直性脊柱炎发生结核的风险[J].中华风湿病学杂志,2006,10(10):607-610. 被引量:18
  • 4Kloesch B, Becker T, Dietersdorfer E, et al. Anti-iIfflammatory and apoptotic effects of the polyphenol curcumin on human fibroblast- like synoviocytes [ J]. Int Immunopharmacol, 2013, 15 ( 2 ) : 400.
  • 5Hara M, Ishiguro N, Katayama K, et al. Safety and efficacy of combi- nation therapy of iguratimod with methotrexate for patients with ac- tive rheumatoid arthritis with an inadequate response to methotrex- ate : an open-label extension of a randomized, double-blind, placebo- controlled trial[J]. Mod Rheumatol,2014,24(3) :410 -418.
  • 6Mucke HA. Iguratimod:a new disease-modifying antirheumatie drug [J]. Drugs Today,2012,48(9) :577 -586.
  • 7Okamura K, Yonemoto Y, Okura C, et al. Efficacy of the clinical use of iguratimod therapy in patients with rheumatoid arthritis [ J ]. Mod Rheumato1,2015,25 (2) :235 - 240.
  • 8Hu W, Xia LJ, Chen FH, et al. Recombinant human endostatin in- hibits adjuvant arthritis by down-regulating VEGF expression and- suppression of TNF-α, IL-1β production [ J ]. Inflamm Res,2012,61 (8) :827 - 835.
  • 9Maruotti N, Cantatore FP, Ribatti D. Putative effects of potentially anti-angiogenic drugs in rheumatic diseases [ J ]. Eur J Clin Pharma- col ,2014,70 ( 2 ) : 135 - 140.
  • 10Sullivan S. Iguratimod: novel DMARD promising for rheumatoid ar- thritis [ J ]. Inpharma,2004,7 : 1450.

共引文献105

同被引文献18

引证文献1

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部